**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 86320

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Predictive value of frailty assessment tools in patients undergoing surgery for gastrointestinal cancer: An observational cohort study**

Zhang HP *et al*. Predictive value of frailty assessment tools

Hui-Pin Zhang, Hai-Lin Zhang, Xiao-Min Zhou, Guan-Jie Chen, Qi-Fan Zhou, Jie Tang, Zi-Ye Zhu, Wei Wang

**Hui-Pin Zhang,** Department of Gastrointestinal Surgery, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang 222061, Jiangsu Province, China

**Hui-Pin Zhang, Wei Wang,** Department of Gastrointestinal Surgery, The First People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, China

**Hai-Lin Zhang, Xiao-Min Zhou, Zi-Ye Zhu,** Department of Nursing, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang 222061, Jiangsu Province, China

**Guan-Jie Chen,** Department of Invasive Technology, Zhongda Hospital Southeast University, Nanjing 210003, Jiangsu Province, China

**Qi-Fan Zhou, Jie Tang,** Department of Hemopurification Center, Lianyungang Clinical College of Nanjing Medical University, Lianyungang 222061, Jiangsu Province, China

**Author contributions:** Zhang HP, Zhang HL, and Chen GJ designed the study; Zhang HP and Zhou XM collected data; Zhang HP wrote the manuscript; Zhang HL, Chen GJ, Zhou QF, and Wang W revised the manuscript; Tang J and Zhu ZY analysed the data; and all authors read and approved the final manuscript.

**Supported by** the Postgraduate Research & Practice Innovation Program of Jiangsu Province, No. SJCX22\_1293; and Lianyungang City Aging Health Research Project, No. L202206.

**Corresponding author: Hai-Lin Zhang, MM, President, Professor,** Department of Nursing, The Affiliated Lianyungang Hospital of Xuzhou Medical University, No. 6 Zhenhua East Road, Haizhou District, Lianyungang 222061, Jiangsu Province, China. luckihailin@163.com

**Received:** June 12, 2023

**Revised:** September 9, 2023

**Accepted:** September 26, 2023

**Published online:** November 27, 2023

**Abstract**

BACKGROUND

Few studies have simultaneously compared the predictive value of various frailty assessment tools for outcome measures in patients undergoing gastrointestinal cancer surgery. Therefore, it is difficult to determine which assessment tool is most relevant to the prognosis of this population.

AIM

To investigate the predictive value of three frailty assessment tools for patient prognosis in patients undergoing gastrointestinal cancer surgery.

METHODS

This single-centre, observational, prospective cohort study was conducted at the Affiliated Lianyungang Hospital of Xuzhou Medical University from August 2021 to July 2022. A total of 229 patients aged ≥ 18 years who underwent surgery for gastrointestinal cancer were included in this study. We collected baseline data on the participants and administered three scales to assess frailty: The comprehensive geriatric assessment (CGA), Fried phenotype and FRAIL scale. The outcome measures were the postoperative severe complications and increased hospital costs.

RESULTS

The prevalence of frailty when assessed with the CGA was 65.9%, 47.6% when assessed with the Fried phenotype, and 34.9% when assessed with the FRAIL scale. Using the CGA as a reference, kappa coefficients were 0.398 for the Fried phenotype and 0.291 for the FRAIL scale (both *P* < 0.001). Postoperative severe complications and increased hospital costs were observed in 29 (12.7%) and 57 (24.9%) patients, respectively. Multivariate logistic analysis confirmed that the CGA was independently associated with increased hospital costs (odds ratio = 2.298, 95% confidence interval: 1.044-5.057; *P* = 0.039). None of the frailty assessment tools were associated with postoperative severe complications.

CONCLUSION

The CGA was an independent predictor of increased hospital costs in patients undergoing surgery for gastrointestinal cancer.

**Key Words:** Gastrointestinal cancer; Frailty; Assessment tools; Prognostic; Complication; Hospital costs

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang HP, Zhang HL, Zhou XM, Chen GJ, Zhou QF, Tang J, Zhu ZY, Wang W. Predictive value of frailty assessment tools in patients undergoing surgery for gastrointestinal cancer: An observational cohort study. *World J Gastrointest Surg* 2023; 15(11): 2525-2536

**URL:** https://www.wjgnet.com/1948-9366/full/v15/i11/2525.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i11.2525

**Core Tip:** Few studies have simultaneously compared the predictive value of various frailty assessment tools for the prognosis in patients undergoing gastrointestinal cancer surgery. Therefore, we investigated the predictive power of the comprehensive geriatric assessment (CGA), Fried phenotype and FRAIL scale for the prognosis of patients undergoing surgery for gastrointestinal cancer. There was a high prevalence of preoperative frailty. Scores on the CGA were positively related to patients’ increased hospital costs.

**INTRODUCTION**

Gastric and colorectal cancers have high morbidity and mortality rates in China and are a heavy burden on China’s population health[1]. Surgery is the mainstay of treatment for patients with gastrointestinal cancer; however, surgical stress poses a challenge to patients[2,3]. It is important to identify the factors that affect postoperative adverse outcomes of patients, which can help us recognise the importance of frailty in evaluating patients before surgery. This can also provide a theoretical basis for formulating corresponding intervention measures. As such, frailty has gradually become a concern in recent years. It is considered a group of syndromes caused by a decreased physiological reserve or multi-system disorder resulting in increased vulnerability and weakened stress tolerance[4]. When frail patients attempt to cope with stressors (*e.g.,* surgery), it can easily lead to disability, falls, fractures and other adverse clinical outcomes. McGovern *et al*[5] and Ding *et al*[6] found that patients undergoing colorectal and gastric cancer surgery had a large range of difference in their prevalence of preoperative frailty, but it remained at a high level of 12.0% to 56.0% and 8.5% to 45.9%, respectively. Frailty was found to be an independent predictor of postoperative complications, mortality and overall survival in patients undergoing gastrointestinal cancer surgery[7-11]. It should be noted that frail patients may increase the incidence of severe complications due to their decreased ability to cope with stress, and frailty has the potential to compromise patient recovery following surgery, thereby increasing the cost of associated treatment, care and medications.

Currently, there is no consensus on the best frailty screening tool for surgical patients with gastrointestinal cancer[12]. Clegg *et al*[13] stated that the comprehensive geriatric assessment (CGA) is the gold standard for frailty assessment. The CGA includes multiple dimensions and is widely recommended for clinical use. However, the CGA is time consuming and requires a professionally trained healthcare provider. The Fried phenotype proposed by Fried was endorsed by the American College of Surgeons and the American Geriatrics Society for preoperative frailty assessment[14]. The Fried phenotype assessment is based on both self-assessment and objective measures and is a commonly used frailty assessment tool in clinical practice[15]. However, because the Fried phenotype assessment measures patients’ physical activity, it can only be performed by medically stable and ambulatory patients. The FRAIL scale, proposed by the International Association for Nutrition, Health, and Aging, is recommended for frailty screening by the Australian and New Zealand Society for Sarcopenia and Frailty Research[16]. The FRAIL scale is based on patient self-report and is simple and quick to complete, facilitating clinical implementation. However, it does not distinguish between frailty and comorbidities. Interestingly, the FRAIL scale has, to date, not been used for patients undergoing gastrointestinal cancer surgery.

These three scales have their own advantages and disadvantages and differ in terms of items and dimensions. Few studies have simultaneously compared the predictive value of the three frailty assessment tools for patient prognosis. Therefore, it is difficult to determine which assessment tool is most relevant to the prognosis of patients undergoing gastrointestinal cancer surgery[17,18]. Thus, we prospectively analysed whether the three frailty scales were predictive of postoperative severe complications and increased hospital costs of patients undergoing gastrointestinal cancer surgery. We also determined which assessment tool was most associated with the measured outcomes by odds ratio.

**MATERIALS AND METHODS**

***Patients***

This single-centre, observational, prospective cohort study was conducted at the Lianyungang Hospital of Xuzhou Medical University from August 2021 to July 2022. The inclusion criteria were as follows: (1) Age ≥ 18 years; (2) Patients whose first pathological diagnosis was gastric, colon or rectal cancer; (3) Patients who underwent elective radical surgery; and (4) Patients who had complete clinical data that could be obtained. The exclusion criteria were as follows: (1) Patients who had cancer combined with other sites of malignant cancers; (2) Patients with a psychiatric history; and (3) Patients who were unable to cooperate with and complete data collection. The study was approved by the Ethics Committee of the Affiliated Lianyungang Hospital of Xuzhou Medical University, Jiangsu, China (ethics approval number: KY-20211029001-01) and was performed in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants in this study.

***Measures***

**CGA:** A CGA typically assesses comorbidities, polypharmacy, functional status, cognition, psychological status and nutritional status[19-21]. In this study, the assessment tools and cut-off values included in the CGA were as follows: Charlson Comorbidity Index (CCI) ≥ 3 was considered multimorbidity[22]; ≥ 5 types of medication prescribed was classified as polypharmacy[22]; Barthel index (BI) < 100 or instrumental activities of daily living < 8 was considered impaired functional status[22,23]; cognition was assessed using the Mini-Mental State Examination, and cognitive impairment was defined according to the patient’s education, in which illiteracy was ≤ 17, primary education was ≤ 20 and junior high school education or above was ≤ 24[24]; the Hospital Anxiety and Depression Scale was used to assess anxiety and depression, and anxiety scores or depression scores ≥ 8 were considered an impaired psychological status[25]; a Patient-Generated Subjective Global Assessment score ≤ 4 was considered malnutrition[26]. Based on previous studies, impairment in ≥ 2 domains within the CGA was defined as frailty[19,21].

**Fried phenotype:** The Fried phenotype includes five items: Weight loss, slowness, exhaustion, low physical activity and weakness. Handgrip strength was measured using an electronic handgrip dynamometer (EH101, Xiangshan, China); activity was assessed using the short form of the International Short Physical Activity Questionnaire[27]; and the criteria for other items were based on the Taiwanese version of the Fried phenotype cut-off[28]. Regarding scoring, there is one point per item according to the assessment criteria of said item. The total score can range from 0-5, with a score of 0 indicating robust, 1-2 indicating pre-frailty, and ≥ 3 indicating frailty[29]. Patients with Fried phenotype scores ≥ 3 were included in the frailty group and those with Fried phenotype scores of 0-2 were included in the non-frailty group[30].

**FRAIL scale:** The FRAIL scale includes five items: Fatigue, resistance, illness, ambulation and weight loss. The items are based on patients’ self-assessment. There is one point for each item. The total score can range from 0-5, with 0 indicating robust, 1-2 indicating pre-frailty, and ≥ 3 indicating frailty[31]. Patients who scored ≥ 3 on the FRAIL scale were included in the frailty group and those who scored 0 to 2 were included in the non-frailty group[32].

***Clinical data collection***

Data collection was performed one day before surgery and included: (1) Baseline demographic data, including age, sex, body mass index (BMI), smoking history, drinking history, upper arm circumference, waist circumference, hip circumference and calf circumference; (2) Clinical data, including cancer type, CCI score, polypharmacy, neoadjuvant therapy, the American Society of Anesthesiologists (ASA) classification, Karnofsky Performance Scale (KPS) score, operative method, operation time, tumour node metastasis (TNM) stage, histological grade and postoperative length of stay; and (3) Laboratory data, including haemoglobin (HB), white blood cell count, platelets, lymphocyte count, lymphocyte ratio, creatinine, haematocrit, albumin and total protein. The scale can be filled out by the patient themselves, or the researcher can inform the patient of the items and help them fill it out. It was necessary to further confirm whether the patient met the inclusion and exclusion criteria after we collected patient data after surgery because the definite TNM stage of the patient and the possible suspension of surgery could not be determined before surgery.

***Outcome measures***

The outcome measures were severe complications and increased hospital costs. Only postoperative severe complications that developed during hospital were considered. Based on previous studies, severe complications were considered as Clavien-Dindo classification ≥ 3[33]. Increased hospital costs were defined as costs greater than the 75th percentile of the entire cohort[6]. All outcome measures were obtained using an electronic information system.

***Sample size***

We calculated the sample size for postoperative severe complications based on a previous study[34], the complication rate was 43% in frail patients and 17% in non-frail patients. We set an *α*-value of 0.05 and a power of 80% to calculate that 96 patients should be included in the study.

***Statistical analysis***

Taking the CGA as a reference, the kappa coefficient was used to analyse its agreement with the Fried phenotype and the FRAIL scale. The measurement data with a normal distribution were described using mean ± SD, and independent samples *t* tests were used for comparison between groups. The measurement data with a biased distribution were described by median and interquartile ranges, and the Mann-Whitney *U* test was used for comparison between groups. The enumeration data were described by frequency and percentage, and the *χ2* test, continuity correction *χ2* test and Mann-Whitney *U* test were used for comparison between groups. Risk factors for severe complications and increased hospital costs were analysed using the above statistical methods and univariate logistic regression. Factors with *P* < 0.10 in the univariate analysis combined with each of the three frailty assessment tools were included in a multivariate logistic regression model. All tests were two-sided, and *P* < 0.05 was considered statistically significant. SPSS version 25.0 (SPSS Inc., Chicago, IL, United States) was used for all statistical analyses.

**RESULTS**

***Baseline patient characteristics***

A total of 229 patients with gastrointestinal cancer who underwent surgery met our inclusion criteria and were enrolled in the study. Severe complications and increased hospital costs were observed in 29 (12.7%) and 57 (24.9%) patients, respectively. There were 13 (5.7%) patients with 3, and 16 (7.0%) patients with 4. The median for hospital costs was 65031 renminbi (RMB), with interquartile ranges of 58125 and 78973 RMB. Among them, 141 (61.6%) were men and 88 (38.4%) were women. Patients were aged 30-88 years, with a mean age of 66.31 years. Patients had a BMI (kg/m2) ranging from 15.56-33.98 kg/m2, with a mean of 23.71 kg/m2. Regarding cancer type, 83 (36.2%) patients had gastric cancer, 81 (35.4%) had colon cancer, and 65 (28.4%) had rectal cancer. Based on the CGA, there were significant differences in age, BMI, CCI score, upper arm circumference, hip circumference, calf circumference, HB, lymphocyte ratio, haematocrit, albumin, ASA classification, KPS score, cancer type, operative method, histological grade, and hospital costs between frail and non-frail patients (all *P* < 0.05). The baseline characteristics of the frail and non-frail patients corresponding to each assessment tool are presented in Table 1.

***Frailty assessment***

The prevalence of preoperative frailty assessed using the CGA, Fried phenotype and FRAIL scale was 65.9%, 47.6% and 34.9%, respectively. Taking the CGA as a reference, kappa coefficients were 0.398 and 0.291 for the Fried phenotype and the FRAIL scale (both *P* < 0.001). Moreover, it showed poor agreement between scales for frailty assessment.

***Univariate analysis of outcome measures***

Our results showed that sex, age, smoking history, drinking history, lymphocyte count, albumin, total protein, ASA classification, and operation time were contributing factors of severe complications (Table 2). Smoking history, neoadjuvant therapy, waist circumference, ASA classification, KPS score, cancer type, histological grade, severe complications and postoperative length of stay were factors influencing increased hospital costs.

***Association of frailty with outcome measures***

The three frailty assessment tools were combined with factors with *P* < 0.10 from the univariate analysis of outcome measures (Table 3). The univariate and multivariate analyses showed that frailty assessed using all assessment tools was not associated with severe complications (all *P* < 0.05). Other independent factors included age, drinking history, albumin and operation time (all *P* < 0.05). Both univariate and multivariate analyses showed that the CGA was associated with increased hospital costs (odds ratio = 2.298, 95% confidence interval: 1.044-5.057; *P* = 0.039). Other independent factors included postoperative length of stay and neoadjuvant therapy (both *P* < 0.05).

**DISCUSSION**

We prospectively analysed whether the three frailty scales predicted severe complications and increased hospital costs in patients undergoing gastrointestinal cancer surgery. Our study revealed the CGA was an independent predictor of increased hospital costs in this population.

Our results showed a high prevalence of preoperative frailty in patients with gastrointestinal cancer undergoing surgery, ranging from 34.9% (FRAIL) to 65.9% (CGA). A study by Chen *et al*[21] found that the prevalence of frailty using the CGA, Geriatric 8 and the Flemish version of the Triage Risk Screening Tool ranged from 40.9% to 75.0% in newly diagnosed all types of cancer patients aged ≥ 20 years, similar to the results of this study. Zhang *et al*[35] showed that the prevalence of preoperative frailty in older adult patients with gastric and colorectal cancer was 43.8%, which is also within the range of our findings. Conversely, Yin *et al*[36] assessed frailty using the 54-item Frailty Index, 9-item Clinical Frailty Scale and FRAIL scale and found that the prevalence of preoperative frailty in older adult patients undergoing elective abdominal surgery was 32.5%, 36.6%, and 43.8%, respectively, which is slightly lower than our findings. This may be related to the fact that our study population included only patients with gastrointestinal cancer. Due to the inherent and therapeutic factors of gastrointestinal cancer, their physiological and psychological reserve abilities are more susceptible to stress, leading to adverse outcomes[35], which likely contribute to the high prevalence of frailty in this population. The poor agreement between the CGA and the Fried phenotype and FRAIL scale showed that there were large differences between assessment tools for the diagnosis of frailty. In addition, the CGA was more sensitive at identifying frailty than the other two scales, possibly because the CGA includes more comprehensive dimensions, these being the physical and psychological dimensions. Psychological problems such as anxiety and depression are more common in cancer patients[37]; thus, the CGA is more sensitive at identifying frailty. The Fried phenotype and the FRAIL scale focus only on the physical dimensions and thus assess the prevalence of frailty as lower than what the CGA would assess[38].

Our study revealed that the CGA, Fried phenotype and FRAIL scale did not independently predict severe complications in patients with gastrointestinal cancer. Reisinger *et al*[39] and Richards *et al*[7] showed that frailty is not an independent influencing factor for severe complications in patients undergoing colorectal cancer surgery (*P* = 0.19 and *P* = 0.62), consistent with our study results. Conversely, the results of Lo *et al*[40] showed that frailty increases the risk of postoperative severe complications. This may be due to differences in the assessment tools used, study populations and geography. Additionally, none of the frailty assessment instruments in our study included a social dimension. Since the global coronavirus disease 2019 pandemic in 2020, social distancing has become an important public health initiative. Social frailty may also have an impact on adverse short-term outcomes in patients. Thus, social frailty items can be used as part of frailty assessment in the future to further explore the elements of frailty assessment tools that can predict postoperative complications in patients undergoing gastrointestinal cancer surgery. This will lead to the creation of more comprehensive assessment tools.

In addition, our study revealed that the CGA scores were positively related to patients’ increased hospital costs. In a cohort study of 52012 adult patients undergoing surgery, Shaw *et al*[41] showed that patients’ frailty led to an increase in healthcare costs by $6048. Lee *et al*[42] stated that hospital costs were higher in frail patients (adjusted odds ratio = 1.46, 95% confidence interval: 1.46-1.46, *P* < 0.001), possibly because of longer hospital stays and more expenditures for rescues and the intensive care unit. Considering that most of the patients in this study made a living through farming and had poor family financial situations, increased hospital costs may have aggravated their psychological and economic burden, thus affecting their attitude towards treatment. Therefore, it is of great significance for us to use the CGA to evaluate patients’ frailty before surgery and provide psychological counselling for them.

Our study has certain strengths. First, this is the first study to use the FRAIL scale to assess frailty in patients with gastrointestinal cancer undergoing surgery. Second, most severe complications occur in hospitals and need to be highly valued, while there are few reports on our population. Third, we used prospective research methods to investigate the predictive value of various frailty assessment tools on patient outcomes, which has not been much reported in previous studies.

Our study had several limitations that need to be noted. First, this was a small, single-centre study, and the conclusions obtained need to be validated in patients from other regions and hospitals. Second, our study population included only patients with gastrointestinal cancer who underwent elective radical surgery. Patients who underwent emergency admission and palliative surgery were not included. Third, we did not analyse the different diseases in gastrointestinal cancer separately.

Finally, based on our study, more long-term outcome measures (including relapse-free survival time and overall survival) should be of interest. In addition, we hope to form a multidisciplinary team including nutritionists, psychologists, rehabilitation therapists, gastrointestinal surgeons, and nurses to help patients develop personalized pre-rehabilitation measures, which can be implemented at home, in the hospital or a combination of both. We should improve the frail state of patients before operation with as little expenditure as possible to reduce the hospitalization expenses of patients. A pre-rehabilitation program suitable for China’s national conditions is urgently needed.

**CONCLUSION**

The prevalence of preoperative frailty was high in patients undergoing gastrointestinal cancer surgery, as assessed by different frailty scales. The CGA is an independent predictor of increased hospital costs in patients undergoing gastrointestinal cancer surgery. It is hoped that our study will arouse the attention of health care providers and the CGA should be included as part of routine preoperative risk assessment in patients undergoing surgery for gastrointestinal cancer.

**ARTICLE HIGHLIGHTS**

***Research background***

Few studies have simultaneously compared the predictive value of various frailty assessment tools for the prognosis in patients undergoing gastrointestinal cancer surgery. Therefore, it is difficult to determine which assessment tool is most relevant to the prognosis of this population.

***Research motivation***

We used three commonly used frailty assessment tools to investigate the status of preoperative frailty and to analyse their predictive value for prognosis in patients undergoing surgery for gastrointestinal cancer.

***Research objectives***

To investigate the predictive value of different frailty assessment tools for postoperative severe complications and increased hospital costs in patients undergoing surgery for gastrointestinal cancer.

***Research methods***

A single-centre, observational, prospective cohort study was conducted at the Affiliated Lianyungang Hospital of Xuzhou Medical University from August 2021 to July 2022. A total of 229 patients aged ≥ 18 years who underwent surgery for gastrointestinal cancer were included in this study. We collected baseline data on the participants and administered three scales to assess frailty: The comprehensive geriatric assessment (CGA), Fried phenotype and FRAIL scale. The outcome measures were postoperative severe complications and increased hospital costs.

***Research results***

The prevalence of frailty when assessed with the CGA was 65.9%, 47.6% when assessed with the Fried phenotype and 34.9% when assessed with the FRAIL scale. Using the CGA as a reference, kappa coefficients were 0.398 for the Fried phenotype and 0.291 for the FRAIL scale (both *P* < 0.001). Postoperative severe complications and increased hospital costs were observed in 29 (12.7%) and 57 (24.9%) patients, respectively. Multivariate logistic analysis confirmed that the CGA was independently associated with increased hospital costs (odds ratio = 2.298, 95% confidence interval: 1.044-5.057; *P* = 0.039). None of the frailty assessment tools were associated with postoperative severe complications.

***Research conclusions***

The CGA has a significant effect on increased hospital costs for patients undergoing gastrointestinal cancer surgery, and should be included as part of routine preoperative risk assessment in this population.

***Research perspectives***

More long-term outcome measures (including relapse-free survival time and overall survival) should be of interest. In addition, there is an urgent need for a pre-rehabilitation program which is suitable for China’s national conditions to improve preoperative frailty in patients undergoing gastrointestinal cancer surgery.

**REFERENCES**

1 **Cao W**, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* 2021; **134**: 783-791 [PMID: 33734139 DOI: 10.1097/CM9.0000000000001474]

2 **Handforth C**, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Ann Oncol* 2015; **26**: 1091-1101 [PMID: 25403592 DOI: 10.1093/annonc/mdu540]

3 **Korc-Grodzicki B**, Downey RJ, Shahrokni A, Kingham TP, Patel SG, Audisio RA. Surgical considerations in older adults with cancer. *J Clin Oncol* 2014; **32**: 2647-2653 [PMID: 25071124 DOI: 10.1200/JCO.2014.55.0962]

4 **Hoogendijk EO**, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. *Lancet* 2019; **394**: 1365-1375 [PMID: 31609228 DOI: 10.1016/S0140-6736(19)31786-6]

5 **McGovern J**, Dolan RD, Horgan PG, Laird BJ, McMillan DC. The prevalence and prognostic value of frailty screening measures in patients undergoing surgery for colorectal cancer: observations from a systematic review. *BMC Geriatr* 2022; **22**: 260 [PMID: 35351011 DOI: 10.1186/s12877-022-02928-5]

6 **Ding L**, Miao X, Lu J, Hu J, Xu X, Zhu H, Xu Q, Zhu S. Comparing the Performance of Different Instruments for Diagnosing Frailty and Predicting Adverse Outcomes among Elderly Patients with Gastric Cancer. *J Nutr Health Aging* 2021; **25**: 1241-1247 [PMID: 34866152 DOI: 10.1007/s12603-021-1701-8]

7 **Richards SJG**, Cherry TJ, Frizelle FA, Eglinton TW. Pre-operative frailty is predictive of adverse post-operative outcomes in colorectal cancer patients. *ANZ J Surg* 2021; **91**: 379-386 [PMID: 32975018 DOI: 10.1111/ans.16319]

8 **Artiles-Armas M**, Roque-Castellano C, Fariña-Castro R, Conde-Martel A, Acosta-Mérida MA, Marchena-Gómez J. Impact of frailty on 5-year survival in patients older than 70 years undergoing colorectal surgery for cancer. *World J Surg Oncol* 2021; **19**: 106 [PMID: 33838668 DOI: 10.1186/s12957-021-02221-6]

9 **Mima K**, Miyanari N, Morito A, Yumoto S, Matsumoto T, Kosumi K, Inoue M, Mizumoto T, Kubota T, Baba H. Frailty is an independent risk factor for recurrence and mortality following curative resection of stage I-III colorectal cancer. *Ann Gastroenterol Surg* 2020; **4**: 405-412 [PMID: 32724884 DOI: 10.1002/ags3.12337]

10 **Shen Y**, Hao Q, Zhou J, Dong B. The impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: a systematic review and meta-analysis. *BMC Geriatr* 2017; **17**: 188 [PMID: 28826406 DOI: 10.1186/s12877-017-0569-2]

11 **Sandini M**, Pinotti E, Persico I, Picone D, Bellelli G, Gianotti L. Systematic review and meta-analysis of frailty as a predictor of morbidity and mortality after major abdominal surgery. *BJS Open* 2017; **1**: 128-137 [PMID: 29951615 DOI: 10.1002/bjs5.22]

12 **Podda M**, Sylla P, Baiocchi G, Adamina M, Agnoletti V, Agresta F, Ansaloni L, Arezzo A, Avenia N, Biffl W, Biondi A, Bui S, Campanile FC, Carcoforo P, Commisso C, Crucitti A, De'Angelis N, De'Angelis GL, De Filippo M, De Simone B, Di Saverio S, Ercolani G, Fraga GP, Gabrielli F, Gaiani F, Guerrieri M, Guttadauro A, Kluger Y, Leppaniemi AK, Loffredo A, Meschi T, Moore EE, Ortenzi M, Pata F, Parini D, Pisanu A, Poggioli G, Polistena A, Puzziello A, Rondelli F, Sartelli M, Smart N, Sugrue ME, Tejedor P, Vacante M, Coccolini F, Davies J, Catena F. Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project. *World J Emerg Surg* 2021; **16**: 35 [PMID: 34215310 DOI: 10.1186/s13017-021-00378-9]

13 **Clegg A**, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013; **381**: 752-762 [PMID: 23395245 DOI: 10.1016/S0140-6736(12)62167-9]

14 **Chow WB**, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF; American College of Surgeons National Surgical Quality Improvement Program; American Geriatrics Society. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. *J Am Coll Surg* 2012; **215**: 453-466 [PMID: 22917646 DOI: 10.1016/j.jamcollsurg.2012.06.017]

15 **Nowak W**, Kowalik I, Kuzin M, Krauze A, Mierzyńska A, Sadowy E, Marcinkiewicz K, Stępińska J. Comparison of the prognostic value of frailty assessment tools in patients aged ≥ 65 years hospitalized in a cardiac care unit with acute coronary syndrome. *J Geriatr Cardiol* 2022; **19**: 343-353 [PMID: 35722033 DOI: 10.11909/j.issn.1671-5411.2022.05.010]

16 **Daly RM**, Iuliano S, Fyfe JJ, Scott D, Kirk B, Thompson MQ, Dent E, Fetterplace K, Wright ORL, Lynch GS, Zanker J, Yu S, Kurrle S, Visvanathan R, Maier AB. Screening, Diagnosis and Management of Sarcopenia and Frailty in Hospitalized Older Adults: Recommendations from the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Expert Working Group. *J Nutr Health Aging* 2022; **26**: 637-651 [PMID: 35718874 DOI: 10.1007/s12603-022-1801-0]

17 **Than TNH**, Nguyen T, Nguyen TTT, Pham T. Frailty and Adverse Outcomes Among Older Patients Undergoing Gastroenterological Surgery in Vietnam. *J Multidiscip Healthc* 2021; **14**: 2695-2703 [PMID: 34594108 DOI: 10.2147/JMDH.S332986]

18 **Penning Y**, El Asmar A, Moreau M, Raspé J, Dal Lago L, Pepersack T, Donckier V, Liberale G. Evaluation of the Comprehensive Geriatric Assessment (CGA) tool as a predictor of postoperative complications following major oncological abdominal surgery in geriatric patients. *PLoS One* 2022; **17**: e0264790 [PMID: 35239731 DOI: 10.1371/journal.pone.0264790]

19 **Bruijnen CP**, Heijmer A, van Harten-Krouwel DG, van den Bos F, de Bree R, Witteveen PO, Emmelot-Vonk MH. Validation of the G8 screening tool in older patients with cancer considered for surgical treatment. *J Geriatr Oncol* 2021; **12**: 793-798 [PMID: 33172806 DOI: 10.1016/j.jgo.2020.10.017]

20 **Tarchand GR**, Morrison V, Klein MA, Watkins E. Use of Comprehensive Geriatric Assessment in Oncology Patients to Guide Treatment Decisions and Predict Chemotherapy Toxicity. *Fed Pract* 2021; **38**: S22-S28 [PMID: 34177238 DOI: 10.12788/fp.0128]

21 **Chen SY**, Chou WC, Lin YC, Tsang NM, Liao KC, Lin CH, Lin JR, Ho YW, Tang WR. Performance of two frailty screening tools among patients with cancer in Taiwan. *Biomed J* 2022; **45**: 361-369 [PMID: 35550341 DOI: 10.1016/j.bj.2021.03.002]

22 **Xue DD**, Cheng Y, Wu M, Zhang Y. Comprehensive geriatric assessment prediction of postoperative complications in gastrointestinal cancer patients: a meta-analysis. *Clin Interv Aging* 2018; **13**: 723-736 [PMID: 29731614 DOI: 10.2147/CIA.S155409]

23 **Mima K**, Imai K, Kaida T, Matsumoto T, Nakagawa S, Sawayama H, Hayashi H, Yamashita YI, Baba H. Impairment of perioperative activities of daily living is associated with poor prognosis following hepatectomy for hepatocellular carcinoma. *J Surg Oncol* 2022; **126**: 995-1002 [PMID: 35796726 DOI: 10.1002/jso.26996]

24 **Kelaiditi E**, Cesari M, Canevelli M, van Kan GA, Ousset PJ, Gillette-Guyonnet S, Ritz P, Duveau F, Soto ME, Provencher V, Nourhashemi F, Salvà A, Robert P, Andrieu S, Rolland Y, Touchon J, Fitten JL, Vellas B; IANA/IAGG. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. *J Nutr Health Aging* 2013; **17**: 726-734 [PMID: 24154642 DOI: 10.1007/s12603-013-0367-2]

25 **Zigmond AS**, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; **67**: 361-370 [PMID: 6880820 DOI: 10.1111/j.1600-0447.1983.tb09716.x]

26 **Ruan X**, Wang X, Zhang Q, Nakyeyune R, Shao Y, Shen Y, Niu C, Zhu L, Zang Z, Wei T, Zhang X, Ruan G, Song M, Miles T, Liu F, Shi H; Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group. The performance of three nutritional tools varied in colorectal cancer patients: a retrospective analysis. *J Clin Epidemiol* 2022; **149**: 12-22 [PMID: 35537604 DOI: 10.1016/j.jclinepi.2022.04.026]

27 **Qu NN**, Li KJ. [Study on the reliability and validity of international physical activity questionnaire (Chinese Vision, IPAQ)]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2004; **25**: 265-268 [PMID: 15200945]

28 **Chan DC**, Tsou HH, Yang RS, Tsauo JY, Chen CY, Hsiung CA, Kuo KN. A pilot randomized controlled trial to improve geriatric frailty. *BMC Geriatr* 2012; **12**: 58 [PMID: 23009149 DOI: 10.1186/1471-2318-12-58]

29 **Fried LP**, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; **56**: M146-M156 [PMID: 11253156 DOI: 10.1093/gerona/56.3.m146]

30 **Palomo I**, García F, Albala C, Wehinger S, Fuentes M, Alarcón M, Arauna D, Montecino H, Mendez D, Sepúlveda M, Fuica P, Fuentes E. Characterization by Gender of Frailty Syndrome in Elderly People according to Frail Trait Scale and Fried Frailty Phenotype. *J Pers Med* 2022; **12** [PMID: 35629135 DOI: 10.3390/jpm12050712]

31 **Morley JE**, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *J Nutr Health Aging* 2012; **16**: 601-608 [PMID: 22836700 DOI: 10.1007/s12603-012-0084-2]

32 **Lv J**, Li R, Yuan L, Yang XL, Wang Y, Ye ZW, Huang FM. Research on the frailty status and adverse outcomes of elderly patients with multimorbidity. *BMC Geriatr* 2022; **22**: 560 [PMID: 35790904 DOI: 10.1186/s12877-022-03194-1]

33 **Okabe H**, Ohsaki T, Ogawa K, Ozaki N, Hayashi H, Akahoshi S, Ikuta Y, Ogata K, Baba H, Takamori H. Frailty predicts severe postoperative complications after elective colorectal surgery. *Am J Surg* 2019; **217**: 677-681 [PMID: 30473227 DOI: 10.1016/j.amjsurg.2018.07.009]

34 **Mazzola M**, Bertoglio C, Boniardi M, Magistro C, De Martini P, Carnevali P, Morini L, Ferrari G. Frailty in major oncologic surgery of upper gastrointestinal tract: How to improve postoperative outcomes. *Eur J Surg Oncol* 2017; **43**: 1566-1571 [PMID: 28669651 DOI: 10.1016/j.ejso.2017.06.006]

35 **Zhang Q**, Zhang M, Hu S, Meng L, Xi J, Xu A, Zhang Y, Yu S. Prevalence and risk factors of preoperative frailty in Chinese elderly inpatients with gastric and colorectal cancer undergoing surgery: a single-center cross-sectional study using the Groningen Frailty Indicator. *Support Care Cancer* 2022; **30**: 677-686 [PMID: 34363109 DOI: 10.1007/s00520-021-06483-4]

36 **Yin Y**, Jiang L, Xue L. Comparison of three frailty measures for 90-day outcomes of elderly patients undergoing elective abdominal surgery. *ANZ J Surg* 2021; **91**: 335-340 [PMID: 33021042 DOI: 10.1111/ans.16357]

37 **Hong JS**, Tian J. Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. *Support Care Cancer* 2014; **22**: 453-459 [PMID: 24091720 DOI: 10.1007/s00520-013-1997-y]

38 **Si H**, Jin Y, Qiao X, Tian X, Liu X, Wang C. Comparison of 6 frailty screening tools in diagnostic properties among Chinese community-dwelling older people. *Geriatr Nurs* 2021; **42**: 276-282 [PMID: 32948340 DOI: 10.1016/j.gerinurse.2020.08.017]

39 **Reisinger KW**, van Vugt JL, Tegels JJ, Snijders C, Hulsewé KW, Hoofwijk AG, Stoot JH, Von Meyenfeldt MF, Beets GL, Derikx JP, Poeze M. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. *Ann Surg* 2015; **261**: 345-352 [PMID: 24651133 DOI: 10.1097/SLA.0000000000000628]

40 **Lo BD**, Leeds IL, Sundel MH, Gearhart S, Nisly GRC, Safar B, Atallah C, Fang SH. Frailer Patients Undergoing Robotic Colectomies for Colon Cancer Experience Increased Complication Rates Compared With Open or Laparoscopic Approaches. *Dis Colon Rectum* 2020; **63**: 588-597 [PMID: 32032198 DOI: 10.1097/DCR.0000000000001598]

41 **Shaw JF**, Mulpuru S, Kendzerska T, Moloo H, Martel G, Eskander A, Lalu MM, McIsaac DI. Association between frailty and patient outcomes after cancer surgery: a population-based cohort study. *Br J Anaesth* 2022; **128**: 457-464 [PMID: 35034792 DOI: 10.1016/j.bja.2021.11.035]

42 **Lee DU**, Kwon J, Han J, Fan GH, Hastie DJ, Lee KJ, Karagozian R. The clinical impact of frailty on the postoperative outcomes of patients undergoing gastrectomy for gastric cancer: a propensity-score matched database study. *Gastric Cancer* 2022; **25**: 450-458 [PMID: 34773519 DOI: 10.1007/s10120-021-01265-7]

**Footnotes**

**Institutional review board statement:** The study was approved by the Ethics Committee of the Affiliated Lianyungang Hospital of Xuzhou Medical University (ethics approval number: KY-20211029001-01).

**Informed consent statement:** Informed consent was obtained from all participants in this study.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The datasets used or analysed during the current study are available from the corresponding authors on reasonable request.

**STROBE statement:** The authors have read the STROBE guidelines, and the manuscript was prepared and revised according to the STROBE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 12, 2023

**First decision:** August 26, 2023

**Article in press:** September 26, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): E

**P-Reviewer:** Koller T, Slovakia; Kono Y, Japan; Sandrucci S, Italy; Tasijawa FA, Indonesia; Tenreiro N, Portugal **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ

**Table 1 Baseline patient characteristics**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Comprehensive geriatric assessment** | | | **Fried phenotype** | | | **FRAIL scale** | | |
| **Non-frail (*n =* 78)** | **Frail (*n =* 151)** | ***P* value** | **Non-frail (*n =* 120)** | **Frail (*n =* 109)** | ***P* value** | **Non-frail (*n =* 149)** | **Frail (*n =* 80)** | ***P* value** |
| Male, *n* (%) | 53 (67.9) | 88 (58.3) | 0.154 | 78 (65.0) | 63 (57.8) | 0.263 | 96 (64.4) | 45 (56.3) | 0.225 |
| Age, yr | 66 (57-71) | 68 (62-76) | 0.020 | 65 (57-71) | 70 (63-76) | < 0.001 | 66 (58-72) | 69 (63-76) | 0.012 |
| BMI, kg/m2 | 24.45 ± 3.47 | 23.33 ± 3.39 | 0.021 | 24.35 ± 3.12 | 23.0 ± 3.68 | 0.003 | 23.95 ± 3.27 | 23.27 ± 3.75 | 0.158 |
| Smoking history, *n* (%) | 35 (44.9) | 71 (47.0) | 0.757 | 62 (51.7) | 44 (40.4) | 0.087 | 76 (51.0) | 30 (37.5) | 0.051 |
| Drinking history, *n* (%) | 32 (41.0) | 68 (45.0) | 0.562 | 61 (50.8) | 39 (35.8) | 0.022 | 70 (47.0) | 30 (37.5) | 0.168 |
| Neoadjuvant therapy, *n* (%) | 2 (2.6) | 10 (6.6) | 0.321 | 4 (3.3) | 8 (7.3) | 0.174 | 5 (3.4) | 7 (8.8) | 0.151 |
| CCI score, *n* (%) | 78 (100) |  | 0.001 |  |  | 0.091 |  |  | 0.003 |
| 0-2 | 0 (0) | 133 (88.1) |  | 114 (95.0) | 97 (89.0) |  | 143 (96.0) | 68 (85.0) |  |
| ≥ 3 | 0 (0) | 18 (11.9) |  | 6 (5.0) | 12 (11.0) |  | 6 (4.0) | 12 (15.0) |  |
| Polypharmacy, *n* (%) |  | 6 (4.0) | 0.178 | 1 (0.8) | 5 (4.6) | 0.173 | 0 (0) | 6 (7.5) | 0.003 |
| Upper arm circumference, cm | 29.5 ± 2.5 | 28.2 ± 2.9 | 0.001 | 29.3 ± 2.4 | 27.8 ± 3.1 | < 0.001 | 29.1 ± 2.6 | 27.8 ± 3.1 | 0.001 |
| Waist circumference, cm | 89.8 ± 9.8 | 87.5 ± 9.7 | 0.091 | 89 ± 39.4 | 87.1 ± 10.0 | 0.099 | 88.7 ± 9.8 | 87.3 ± 9.6 | 0.303 |
| Hip circumference, cm | 96.4 ± 6.3 | 93.6 ± 7.4 | 0.006 | 96.0 ± 6.0 | 92.9 ± 7.9 | 0.001 | 95.1 ± 6.7 | 93.7 ± 7.9 | 0.157 |
| Calf circumference, cm | 34.8 ± 3.2 | 33.0 ± 3.4 | < 0.001 | 34.8 ± 3.0 | 32.3 ± 3.5 | < 0.001 | 34.2 ± 3.2 | 32.5 ± 3.6 | 0.001 |
| HB, g/L | 130 (109-137) | 116 (97-133) | 0.003 | 130 (114-141) | 108 (92-128) | < 0.001 | 127 (111-138) | 106 (87-128) | < 0.001 |
| WBC, 109/L | 5.75 (4.50-6.84) | 6.00 (4.70-7.22) | 0.184 | 5.85 (4.52-6.97) | 5.93 (4.72-6.90) | 0.598 | 5.80 (4.53-6.81) | 6.00 (4.76-7.54) | 0.186 |
| Platelet, 1012/L | 209 (178-244) | 228 (186-270) | 0.171 | 212 (181-249) | 228 (186-274) | 0.255 | 219 (179-254) | 227 (190-278) | 0.265 |
| Lymphocyte count, 109/L | 1.56 (1.17-1.97) | 1.39 (1.07-1.77) | 0.070 | 1.47 (1.17-1.96) | 1.40 (1.04-1.74) | 0.046 | 1.44 (1.16-1.94) | 1.40 (0.92-1.74) | 0.067 |
| Lymphocyte ratio, % | 28.6 (23.0-33.0) | 23.5 (18.4-31.3) | 0.002 | 28.2 (21.8-33.3) | 23.4 (17.3-29.1) | 0.003 | 27.6 ± 9.2 | 23.5 ± 9.7 | 0.013 |
| Creatinine, μmmol/L | 63.4 (53.8-71.0) | 58.2 (48.5-72.3) | 0.127 | 63.6 (54.4-73.2) | 55.3 (47.0-67.5) | 0.001 | 62.5 (52.6-72.5) | 56.7 (47.3-69.5) | 0.074 |
| Haematocrit, % | 39.3 (34.1-41.9) | 35.4 (31.3-40.5) | 0.003 | 39.3 (34.9-42.8) | 33.5 (29.4-39.0) | < 0.001 | 38.8 (34.1-41.5) | 32.7 (28.0-39.1) | < 0.001 |
| Albumin, g/L | 38.± 13.7 | 36.4 ± 4.0 | 0.002 | 38.4 ± 3.5 | 35.4 ± 3.9 | < 0.001 | 37.8 ± 3.7 | 35.4 ± 4.0 | < 0.001 |
| Total protein, g/L | 62.7 ± 5.8 | 61.2 ± 5.9 | 0.059 | 62.8 ± 5.6 | 60.5 ± 6.0 | 0.003 | 62.4 ± 5.4 | 60.4 ± 6.6 | 0.011 |
| ASA classification, *n* (%) |  |  | 0.036 |  |  | 0.009 |  |  | 0.011 |
| I-II | 55 (70.5) | 85 (56.3) |  | 83 (69.2) | 57 (52.3) |  | 100 (67.1) | 40 (50.0) |  |
| III-IV | 23 (29.5) | 66 (43.7) |  | 37 (30.8) | 52 (47.7) |  | 49 (32.9) | 40 (50.0) |  |
| KPS score, *n* (%) |  |  | < 0.001 |  |  | < 0.001 |  |  | < 0.001 |
| ≥ 70 | 76 (97.4) | 118 (78.1) |  | 119 (99.2) | 75 (68.8) |  | 144 (96.6) | 50 (62.5) |  |
| < 70 | 2 (2.6) | 33 (21.9) |  | 1 (0.8) | 34 (31.2) |  | 5 (3.4) | 30 (37.5) |  |
| Cancer type, *n* (%) |  |  | 0.011 |  |  | 0.216 |  |  | 0.104 |
| Stomach | 18 (23.1) | 65 (43.0) |  | 40 (33.3) | 43 (39.4) |  | 49 (32.9) | 34 (42.5) |  |
| Colon | 32 (41.0) | 49 (32.5) |  | 40 (33.3) | 41 (37.6) |  | 51 (34.2) | 30 (37.5) |  |
| Rectum | 28 (35.9) | 37 (24.5) |  | 40 (33.3) | 25 (22.9) |  | 49 (32.9) | 16 (20.0) |  |
| Operative method, *n* (%) |  |  | 0.005 |  |  | 0.008 |  |  | 0.187 |
| Open surgery | 13 (16.7) | 52 (34.4) |  | 25 (20.8) | 40 (36.7) |  | 38 (25.5) | 27 (33.8) |  |
| Laparoscopic surgery | 65 (83.3) | 99 (65.6) |  | 95 (79.2) | 69 (63.3) |  | 111 (74.5) | 53 (66.3) |  |
| Operative time, min | 156 (123-202) | 169 (120-210) | 0.578 | 165 (120-217) | 163 (121-195) | 0.486 | 165 (125-210) | 160 (119-200) | 0.412 |
| TNM stage, *n* (%) |  |  | 0.057 |  |  | 0.328 |  |  | 0.911 |
| I-II | 55 (70.5) | 87 (57.6) |  | 78 (65.0) | 64 (58.7) |  | 92 (61.7) | 50 (62.5) |  |
| III | 23 (29.5) | 64 (42.4) |  | 42 (35.0) | 45 (41.3) |  | 57 (38.3) | 30 (37.5) |  |
| Histological grade, *n* (%) |  |  | 0.012 |  |  | 0.545 |  |  | 0.374 |
| Poorly differentiated | 28 (35.9) | 78 (51.7) |  | 55 (45.8) | 51 (46.8) |  | 67 (45.0) | 39 (48.8) |  |
| Moderately differentiated | 33 (42.3) | 55 (36.4) |  | 43 (35.8) | 45 (41.3) |  | 56 (37.6) | 32 (40.0) |  |
| Highly differentiated | 17 (21.8) | 18 (11.9) |  | 22 (18.3) | 13 (11.9) |  | 26 (17.4) | 9 (11.3) |  |
| Postoperative length of stay, d | 14 (12, 16) | 14 (12, 19) | 0.184 | 14 (12, 18) | 15 (13, 18) | 0.162 | 14 (12, 17) | 15 (13, 19) | 0.029 |
| Hospital costs, RMB | 62341 (58067, 71180) | 67697 (59097, 81720) | 0.006 | 63148 (57893, 74841) | 67764 (59156, 82804) | 0.047 | 63477 (57719, 76170) | 69031 (59596, 82043) | 0.023 |
| Severe complications, *n* (%) | 6 (7.7) | 23 (15.2) | 0.104 | 13 (10.8) | 16 (14.7) | 0.382 | 16 (10.7) | 13 (16.3) | 0.232 |

Data are presented as means ± SD, medians (interquartile ranges) or *n* (%).

CCI: Charlson Comorbidity Index; BMI: Body mass index; HB: Haemoglobin; WBC: White blood cell; ASA: American Society of Anesthesiologists; KPS: Karnofsky Performance Scale; TNM: Tumour node metastasis.

**Table 2 Predictors of severe complications and increased hospital costs (univariate analysis)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Severe complications (-) (*n =* 200)** | **Severe complications (+) (*n =* 29)** | ***P* value** | **OR (95%CI)** | ***P* value** | **increased hospital costs (-) (*n =* 172)** | **increased hospital costs (+) (*n =* 57)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| Male, *n* (%) | 119 (59.5) | 22 (79.5) | 0.090 | 0.467 (0.191, 1.145) | 0.096 | 101 (58.7) | 40 (70.2) | 0.123 | 0.605 (0.318, 1.151) | 0.125 |
| Age, yr | 66 (58-73) | 70 (65-77) | 0.004 | 1.070 (1.022, 1.120) | 0.004 | 67 (58, 73) | 68 (64, 74) | 0.212 | 1.024 (0.993, 1.056) | 0.124 |
| BMI, kg/m2 | 23.52 (21.22-25.72) | 23.73 (21.22-26.64) | 0.588 | 1.024 (0.916, 1.146) | 0.671 | 23.52 (21.28, 25.53) | 23.59 (20.83, 26.30) | 0.876 | 0.993 (0.911, 1.084) | 0.883 |
| Smoking history, *n* (%) | 87 (43.5) | 19 (65.5) | 0.026 | 2.468 (1.092, 5.576) | 0.030 | 73 (42.4) | 33 (57.9) | 0.043 | 1.865 (1.017, 3.420) | 0.044 |
| Drinking history, *n* (%) | 81 (40.5) | 19 (65.5) | 0.011 | 2.791 (1.234, 6.313) | 0.014 | 70 (40.7) | 30 (52.6) | 0.115 | 1.619 (0.886, 2.957) | 0.117 |
| Neoadjuvant therapy, *n* (%) | 12 (6.0) | 0 (0) | 0.363 | NA1 |  | 5 (2.9) | 7 (12.3) | 0.016 | 4.676 (1.422, 15.376) | 0.011 |
| CCI score, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| 0-2 | 184 (92.0) | 27 (93.1) | 1.000 | 0.852 (0.185, 3.912) | 0.837 | 158 (91.9) | 53 (93.0) | 1.000 | 0.852 (0.269, 2.701) | 0.785 |
| ≥ 3 | 16 (8.0) | 2 (6.9) | 1.000 | 1.393 (0.157, 12.362) | 0.766 | 14 (8.1) | 4 (7.0) | 0.336 | 3.130 (0.614, 15.963) | 0.170 |
| Polypharmacy, *n* (%) | 5 (2.5) | 1 (3.4) |  |  |  | 3 (1.7) | 3 (5.3) |  |  |  |
| Upper arm circumference, cm | 28.7 ± 2.8 | 28.3 ± 3.3 | 0.453 | 0.949 (0.827, 1.088) | 0.452 | 28.6 ± 2.8 | 28.8 ± 2.9 | 0.633 | 1.026 (0.923, 1.140) | 0.632 |
| Waist circumference, cm | 87.9 ± 9.4 | 90.3 ± 11.9 | 0.318 | 1.025 (0.985, 1.067) | 0.226 | 87.6 ± 9.7 | 90.1 ± 9.7 | 0.094 | 1.027 (0.995, 1.059) | 0.095 |
| Hip circumference, cm | 94.0 (90.7-98.8) | 96.0 (89.5-101.3) | 0.454 | 0.998 (0.945, 1.054) | 0.938 | 94.5 ± 7.0 | 94.9 ± 7.6 | 0.663 | 1.009 (0.968, 1.053) | 0.661 |
| Calf circumference, cm | 33.8 (31.5-35.9) | 34.6 (31.8-37.5) | 0.719 | 0.989 (0.883, 1.107) | 0.843 | 33.6 ± 3.4 | 33.7 ± 3.5 | 0.768 | 1.013 (0.928, 1.106) | 0.766 |
| HB, g/L | 121 (103-135) | 119 (100-135) | 0.872 | 0.998 (0.982, 1.015) | 0.836 | 124 (104, 135) | 112 (97, 134) | 0.208 | 0.992 (0.979, 1.005) | 0.206 |
| WBC, 109/L | 5.91 (4.71-6.99) | 5.93 (4.20-6.68) | 0.441 | 0.952 (0.782, 1.158) | 0.621 | 5.85 (4.52, 7.03) | 5.96 (5.14, 6.85) | 0.557 | 1.008 (0.874, 1.162) | 0.917 |
| Platelet, 1012/L | 221 (182-263) | 204 (168-247) | 0.279 | 0.996 (0.990, 1.001) | 0.147 | 220 (183, 260) | 227 (168, 270) | 0.809 | 0.999 (0.995, 1.003) | 0.652 |
| Lymphocyte count, 109/L | 1.47 (1.16-1.88) | 1.22 (1.03-1.77) | 0.057 | 0.483 (0.218, 1.067) | 0.072 | 1.42 (1.10, 1.84) | 1.46 (1.20, 1.87) | 0.509 | 1.043 (0.620, 1.756) | 0.873 |
| Lymphocyte ratio, % | 26.4 ± 9.5 | 24.0 ± 9.8 | 0.198 | 0.972 (0.931, 1.015) | 0.198 | 25.3 (20.4, 32.5) | 23.6 (18.6, 31.3) | 0.581 | 0.999 (0.968, 1.031) | 0.962 |
| Creatinine, μmmol/L | 59.8 (49.8-71.4) | 65.7 (55.1-71.3) | 0.244 | 1.008 (0.992, 1.023) | 0.342 | 59.8 (50.5, 71.4) | 61.1 (49.9, 71.0) | 0.896 | 0.993 (0.977, 1.010) | 0.408 |
| Haematocrit, % | 37.2 (32.1-41.0) | 35.9 (30.3-41.5) | 0.981 | 0.994 (0.935, 1.058) | 0.859 | 37.8 (32.5, 41.1) | 35.0 (31.2, 41.1) | 0.294 | 0.973 (0.928, 1.021) | 0.262 |
| Albumin, g/L | 37.3 ± 3.9 | 34.9 ± 4.1 | 0.002 | 0.856 (0.772, 0.948) | 0.003 | 37.2 ± 3.8 | 36.4 ± 4.3 | 0.236 | 0.955 (0.885, 1.030) | 0.236 |
| Total protein, g/L | 61.8 (58.3-65.8) | 58.9 (56.6-62.4) | 0.012 | 0.921 (0.857, 0.989) | 0.023 | 61.6 (58.0, 65.3) | 60.5 (57.6, 64.7) | 0.977 | 1.015 (0.965, 1.068) | 0.567 |
| ASA classification, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| I-II | 127 (63.5) | 13 (44.8) | 0.054 | 2.141 (0.975, 4.701) | 0.058 | 112 (65.1) | 28 (49.1) | 0.032 | 1.933 (1.054, 3.546) | 0.033 |
| III-IV | 73 (36.5) | 16 (55.2) |  |  |  | 60 (34.9) | 29 (50.9) |  |  |  |
| KPS score, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| ≥ 70 | 170 (85.0) | 24 (82.8) | 0.970 | 1.181 (0.418, 3.336) | 0.754 | 150 (87.2) | 44 (77.2) | 0.069 | 2.014 (0.939, 4.323) | 0.072 |
| < 70 | 30 (15.0) | 5 (17.2) |  |  |  | 22 (12.8) | 13 (22.8) |  |  |  |
| Cancer type, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| Stomach | 74 (37.0) | 9 (31.0) | 0.743 | Reference |  | 56 (32.6) | 27 (47.4) | 0.114 | Reference |  |
| Colon | 69 (34.5) | 12 (41.4) |  | 1.430 (0.567, 3.604) | 0.448 | 63 (36.6) | 18 (31.6) |  | 0.593 (0.295, 1.189) | 0.141 |
| Rectum | 57 (28.5) | 8 (27.6) |  | 1.154 (0.419, 3.178) | 0.782 | 53 (30.8) | 12 (21.1) |  | 0.470 (0.216, 1.021) | 0.057 |
| Operative method, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| Open surgery | 58 (29.0) | 7 (24.1) | 0.587 | 1.284 (0.520, 3.169) | 0.588 | 52 (30.2) | 13 (22.8) | 0.281 | 1.467 (0.729, 2.951) | 0.283 |
| Laparoscopic surgery | 142 (71.0) | 22 (75.9) |  |  |  | 120 (69.8) | 44 (77.2) |  |  |  |
| Operative time, min | 159 (120-202) | 180 (135-225) | 0.097 | 1.006 (1.000, 1.012) | 0.053 | 157 (120, 196) | 170 (131, 220) | 0.157 | 1.004 (0.999, 1.009) | 0.112 |
| TNM stage, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| I-II | 124 (62.0) | 18 (62.1) | 0.994 | 0.997 (0.447, 2.225) | 0.994 | 111 (64.5) | 31 (54.4) | 0.171 | 1.526 (0.831, 2.802) | 0.173 |
| III | 76 (38.0) | 11 (37.9) |  |  |  | 61 (35.5) | 26 (45.6) |  |  |  |
| Histological grade, *n* (%) |  |  |  |  |  |  |  |  |  |  |
| Poorly differentiated | 91 (45.5) | 15 (51.7) | 0.322 | 0.725 (0.408, 1.287) | 0.272 | 74 (43.0) | 32 (56.1) | 0.073 | 0.674 (0.434, 1.048) | 0.080 |
| Moderately differentiated | 76 (38.0) | 12 (41.4) |  |  |  | 69 (40.1) | 19 (33.3) |  |  |  |
| Highly differentiated | 33 (16.5) | 2 (6.9) |  |  |  | 29 (16.9) | 6 (10.5) |  |  |  |
| Severe complications, *n* (%) | - | - | - | - | - | 14 (8.1) | 15 (26.3) | < 0.001 | 4.031 (1.804, 9.005) | 0.001 |
| Postoperative length of stay, d | - | - | - | - | - | 14 (12, 16) | 17 (14, 24) | < 0.001 | 1.160 (1.094, 1.229) | < 0.001 |

1NA: Low number of observations.

Data are presented as means ± SD, medians (interquartile ranges) or *n* (%). CCI: Charlson Comorbidity Index; BMI: Body mass index; HB: Haemoglobin; WBC: White blood cell; ASA: American Society of Anesthesiologists; KPS: Karnofsky Performance Scale; TNM: Tumour node metastasis; OR: Odds ratio; CI: Confidence interval.

**Table 3 Impact of frailty on severe complications and increased hospital costs by the multivariate logistic regression**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Frail group** | **Non-frail group** | **Univariate** | | **Multivariate** | | |
| **Frailty: OR (95%CI)** | ***P* value** | **Frailty: OR (95%CI)** | ***P* value** | **Other significant predictors, OR (95%CI), *P* value** |
| Severe complications |  |  |  |  |  |  |  |
| Comprehensive geriatric assessment, *N =* 151, *n =* 78 | 23 (15.2) | 6 (7.7) | 2.156 (0.839, 5.541) | 0.111 | - | - | Age: 1.064 (1.010, 1.122); *P* = 0.019. Drinking history: 3.649 (1.504, 8.855); *P* = 0.004. Albumin: 0.880 (0.783, 0.989); *P* = 0.032. Operative time: 1.008 (1.001, 1.015); *P* = 0.022 |
| Fried phenotype, *N =* 109, *n =* 120 | 16 (14.7) | 13 (10.8) | 1.416 (0.647, 3.098) | 0.384 | - | - | Age: 1.064 (1.010, 1.122); *P* = 0.019. Drinking history: 3.649 (1.504, 8.855); *P* = 0.004. Albumin: 0.880 (0.783, 0.989); *P* = 0.032. Operative time: 1.008 (1.001, 1.015); *P* = 0.022 |
| FRAIL scale, *N =* 80, *n =* 149 | 13 (16.3) | 16 (10.7) | 1.112 (0.866, 1.428) | 0.406 | - | - | Age: 1.064 (1.010, 1.122); *P* = 0.019. Drinking history: 3.649 (1.504, 8.855); *P* = 0.004. Albumin: 0.880 (0.783, 0.989); *P* = 0.032. Operative time: 1.008 (1.001, 1.015); *P* = 0.022 |
| Increased hospital costs |  |  |  |  |  |  |  |
| Comprehensive geriatric assessment, *N =* 151, *n =* 78 | 46 (30.5) | 11 (14.1) | 2.668 (1.291, 5.513) | 0.008 | 2.298 (1.044, 5.057) | 0.039 | Postoperative length of stay: 1.167 (1.098, 1.241); *P* < 0.001. Neoadjuvant therapy: 5.778 (1.601, 20.860); *P* = 0.007 |
| Fried phenotype, *N =* 109, *n =* 120 | 33 (30.3) | 24 (20.0) | 1.737 (0.948, 3.183) | 0.074 | - | - | Postoperative length of stay: 1.168 (1.100, 1.241); *P* < 0.001. Neoadjuvant therapy: 6.348 (1.792, 22.484); *P* = 0.004 |
| FRAIL scale, *N =* 80, *n =* 149 | 25 (31.3) | 32 (21.5) | 1.662 (0.900, 3.069) | 0.105 | - | - | Postoperative length of stay: 1.168 (1.100, 1.241); *P* < 0.001. Neoadjuvant therapy: 6.348 (1.792, 22.484); *P* = 0.004 |

N: Number in frailty group; n: Number in non-frailty group; OR: Odds ratio; CI: Confidence interval.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**